GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: LY-573636 | LY573636
Compound class:
Synthetic organic
Comment: Tasisulam (LY573636) is an acyl-sulfonamide class compound with anti-tumour activities [2]. It has more recently been reported to behave as a molecular glue degrader of the RBM39 spliceosome protein. This activity proceeds via a proteasome-dependent mechanism that relies on the presence of the cullin RING ligase substrate receptor DCAF15 [1].
|
|
|||||||||||||||||||||||||||||||||||
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| Targets where the ligand is described in the comment field | |
| Target | Comment |
|
RNA binding motif protein 39 in Spliceosome proteins RNA binding motif protein 39 in RNA-binding proteins (RBPs) |
The RBM39 protein is a spliceosome component that has roles in steroid hormone receptor-mediated transcription and alternative splicing. It is a target of pharmaceutical interest based on its ability to modulate the alternative splicing of genes involved in cancer occurrence and progression. The aryl sulfonamides indisulam and tasisulam have been identified as molecular glue class degraders of RBM39. Next-generation RBM39 molecular glue degraders are in development pipelines, including REC-1245 (Recursion; phase 1/2 for advanced solid tumours), and ST-00937 and ST-01156 (Seed Therapeutics; for Ewing sarcoma and other solid tumours) - structures not disclosed as of September 2025. |